Fifth Third Wealth Advisors LLC Has $417,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Fifth Third Wealth Advisors LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 76.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 397 shares of the biopharmaceutical company’s stock after acquiring an additional 172 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $417,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of REGN. Norges Bank acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth $932,571,000. Global Assets Advisory LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $339,594,000. Capital International Investors boosted its holdings in Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares during the last quarter. First Trust Advisors LP grew its position in Regeneron Pharmaceuticals by 115.2% in the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after purchasing an additional 195,902 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of several analyst reports. Truist Financial restated a “buy” rating and issued a $1,200.00 price objective (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Piper Sandler increased their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the stock a “neutral” rating in a report on Monday, July 22nd. Finally, Barclays increased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $1,104.65.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded down $2.79 on Thursday, hitting $1,182.55. 17,691 shares of the company’s stock were exchanged, compared to its average volume of 469,602. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,203.49. The stock has a 50-day moving average of $1,081.59 and a 200-day moving average of $1,000.46. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The stock has a market cap of $130.36 billion, a price-to-earnings ratio of 35.02, a P/E/G ratio of 3.12 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Regeneron Pharmaceuticals’s revenue was up 12.3% compared to the same quarter last year. During the same period last year, the firm posted $8.79 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, EVP Joseph J. Larosa sold 1,866 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the completion of the sale, the executive vice president now directly owns 37,937 shares in the company, valued at $41,311,496.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The disclosure for this sale can be found here. Insiders sold a total of 17,731 shares of company stock worth $18,230,142 in the last three months. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.